Alnylam Pharmaceuticals
ALNY
Market cap $41.1B

314.94 USD

-7.70

2.39%

At close Jul 11, 4:00 PM EDT

After hours

314.94

+0.00

0.00%

1 day

-2.39%

5 days

-4.05%

1 month

5.48%

3 months

32.46%

6 months

21.94%

Year to date

34.81%

1 year

20.66%

5 years

106.19%

10 years

150.67%

About: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Employees: 2,230

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

150% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 10 (+6) [Q1 2025]

58% more first-time investments, than exits

New positions opened: 106 | Existing positions closed: 67

17% more repeat investments, than reductions

Existing positions increased: 231 | Existing positions reduced: 197

15% more call options, than puts

Call options by funds: $274M | Put options by funds: $238M

14% more capital invested

Capital invested by funds: $30B [Q4 2024] → $34.2B (+$4.2B) [Q1 2025]

5% more funds holding

Funds holding: 581 [Q4 2024] → 611 (+30) [Q1 2025]

1.18% less ownership

Funds ownership: 98.98% [Q4 2024] → 97.8% (-1.18%) [Q1 2025]

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$325

3%

upside

Avg. target

$359

14%

upside

High target

$404

28%

upside

9 analyst ratings

8 positive

89%

1 neutral

11%

0 negative

0%

Citigroup David Lebovitz	28%upside $404	Buy Maintained	11 Jul 2025
B of A Securities Tazeen Ahmad	14%upside $359	Buy Maintained	11 Jul 2025
Jefferies Maury Raycroft	22%upside $384	Buy Maintained	7 Jul 2025
Wells Fargo Tiago Fauth	6%upside $333	Equal-Weight Maintained	30 Jun 2025
Needham Joseph Stringer	20%upside $377	Buy Maintained	26 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ALNY published over the past 30 days

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

Alnylam Pharmaceuticals ALNY is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure.

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

Alnylam Pharmaceuticals Names Garg R&D Chief

Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer.

Alnylam Pharmaceuticals Names Garg R&D Chief

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development Officer to oversee an integrated R&D organization. Building on the launch of AMVUTTRA® in transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Alnylam is entering a new phase of growth, and a combined R&D organization will accelera.

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

Zacks Investment Research

Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM

ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA® (vutrisiran). The approval broadens the indication for AMVUTTRA, which now becomes the first and onl.

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the even.

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

The Motley Fool

3 High-Flying Stocks That Could Soar Even More

Many investors love the "big mo." That's short for "big momentum.

3 High-Flying Stocks That Could Soar Even More

Alnylam Issues 2024 Corporate Responsibility Report

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2024 Corporate Responsibility Report. Guided by the theme of “Accepting Challenges to Improve the Health of Humanity,” Alnylam continues to take meaningful steps across each of its six corporate responsibility pillars. This year's edition highlights the company's progress, data, and stories demonstrating its commitment to patient access,.

Alnylam Issues 2024 Corporate Responsibility Report

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) as a late-breaking abstract at the Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The results demonstrate that vutrisiran, which rapi.

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The latest analyses of the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with card.

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

See News Rankings

Charts implemented using Lightweight Charts™